Sharp Therapeutics Corp. Reports Second Quarter 2025 Results and Expands Market Presence with Listing On OTCQB
Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) has announced its Q2 2025 financial results and its listing on the OTCQB market. The company reported an 85% increase in R&D spending compared to Q2 2024, primarily focused on their Gaucher and Progranulin programs.
The pre-clinical stage company, which develops small-molecule therapeutics for genetic diseases, has expanded its market presence through the OTCQB listing and has applied for DTC eligibility to enhance trading accessibility. Sharp is progressing toward Phase I clinical trials planned for 2026, utilizing its discovery platform that combines high-throughput screening technologies with computationally optimized compound libraries.
Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ha comunicato i risultati finanziari del secondo trimestre 2025 e la sua quotazione sul mercato OTCQB. La societ脿 ha registrato un incremento dell'85% della spesa in R&S rispetto al Q2 2024, concentrata soprattutto sui programmi per la malattia di Gaucher e per Progranulina.
Impresa in fase pre-clinica che sviluppa terapie a piccola molecola per malattie genetiche, Sharp ha ampliato la sua visibilit脿 di mercato grazie alla quotazione OTCQB e ha richiesto l'idoneit脿 DTC per facilitare le negoziazioni. L'azienda procede verso trial clinici di Fase I previsti per il 2026, sfruttando una piattaforma di discovery che integra screening ad alta produttivit脿 con librerie di composti ottimizzate mediante calcolo.
Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ha anunciado sus resultados financieros del segundo trimestre de 2025 y su incorporaci贸n al mercado OTCQB. La compa帽铆a inform贸 un aumento del 85% en gasto de I+D respecto al Q2 de 2024, centrado principalmente en sus programas para Gaucher y Progranulina.
Empresa en fase precl铆nica que desarrolla terapias de peque帽a mol茅cula para enfermedades gen茅ticas, Sharp ha ampliado su presencia en el mercado con la cotizaci贸n en OTCQB y ha solicitado la elegibilidad DTC para facilitar el acceso a la negociaci贸n. Sharp avanza hacia ensayos cl铆nicos de Fase I previstos para 2026, utilizando una plataforma de descubrimiento que combina cribado de alto rendimiento con bibliotecas de compuestos optimizadas por c谩lculo.
Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF)臧� 2025雲� 2攵勱赴 鞛鞁れ爜瓿� OTCQB 靸侅灔鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 2024雲� 2攵勱赴 雽�牍� 鞐瓣惮臧滊皽牍勱皜 85% 歃濌皜頄堧嫟瓿� 氤搓碃頄堨溂氅�, 鞚� 歃濌皜電� 欤茧 瓿犾厰氤�(Gaucher) 氚� 頂勲攴鸽灅雸岆Π(Grn) 頂勲攴鸽灗鞐� 歆戩霅� 瓴冹瀰雼堧嫟.
鞙犾爠歆堩櫂鞖� 鞝�攵勳瀽 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞝勳瀯靸� 雼硠 旮办梾鞚� Sharp電� OTCQB 靸侅灔鞚� 韱淀暣 鞁滌灔 雲胳稖鞚� 頇曤寑頄堨溂氅� 瓯半灅 鞝戧芳靹膘潉 雴掛澊旮� 鞙勴暣 DTC 鞝侁博靹� 鞁犾箔鞚� 鞝滌稖頄堨姷雼堧嫟. 須岇偓電� 瓿犾矘毽焿 鞀ろ伂毽嫕 旮办垹瓿� 瓿勳偘 斓滌爜頇旊悳 頇旐暕氍� 霛检澊敫岆煬毽ゼ 瓴绊暕頃� 氚滉铂 頂岆灚韽检潉 頇滌毄頃橃棳 2026雲� 鞁滍枆 鞓堨爼鞚� 1靸� 鞛勳儊鞁滍棙鞚� 頄ロ暣 雮橃晞臧�瓿� 鞛堨姷雼堧嫟.
Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) a annonc茅 ses r茅sultats financiers du deuxi猫me trimestre 2025 et son inscription sur le march茅 OTCQB. La soci茅t茅 a enregistr茅 une augmentation de 85 % des d茅penses de R&D par rapport au T2 2024, principalement d茅di茅e 脿 ses programmes Gaucher et Progranuline.
Entreprise en phase pr茅clinique d茅veloppant des th茅rapeutiques petites mol茅cules pour des maladies g茅n茅tiques, Sharp a renforc茅 sa pr茅sence sur le march茅 via l'inscription OTCQB et a demand茅 l'茅ligibilit茅 DTC pour faciliter les transactions. Sharp progresse vers des essais cliniques de Phase I pr茅vus en 2026, en s'appuyant sur une plateforme de d茅couverte qui combine des technologies de criblage 脿 haut d茅bit et des biblioth猫ques de compos茅s optimis茅es par calcul.
Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) hat seine Finanzergebnisse f眉r das zweite Quartal 2025 und seine Notierung am OTCQB-Markt bekanntgegeben. Das Unternehmen meldete einen 85%igen Anstieg der F&E-Ausgaben gegen眉ber Q2 2024, der sich haupts盲chlich auf die Programme f眉r Gaucher und Progranulin konzentriert.
Das sich in der pr盲klinischen Phase befindliche Unternehmen, das niedermolekulare Therapeutika f眉r genetische Erkrankungen entwickelt, hat seine Marktpr盲senz durch die OTCQB-Listung ausgebaut und die DTC-Qualifikation beantragt, um den Handel zu erleichtern. Sharp arbeitet auf Phase-I-Studien, geplant f眉r 2026, hin und nutzt dabei eine Discovery-Plattform, die Hochdurchsatz-Screening-Technologien mit rechnerisch optimierten Wirkstoffbibliotheken kombiniert.
- 85% increase in R&D investment year-over-year
- Expansion to OTCQB market enhancing investor accessibility
- Progress toward Phase I clinical trials in 2026
- Pending DTC eligibility to improve trading efficiency
- Still in pre-clinical stage with no immediate revenue generation
- Increased R&D spending may impact cash burn rate
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its condensed interim consolidated financial statements for the three and six months ended June 30, 2025, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated.
The Company also announces that its common shares are now trading under the symbol "SHRXF" on the OTCQB board of OTC Markets, a United States trading platform operated by the OTC Markets Group in New York (the "OTC Listing"). The Company's common shares will continue to trade on the Company's primary market, the TSX Venture Exchange, under the symbol "SHRX". This strategic expansion enhances Sharp's visibility, trading accessibility, and investor reach across North America, opening the door to a broader base of shareholders who the Company believes will recognize the potential of the Company's small-molecule therapeutics for genetic diseases.
Scott Sneddon, Sharp's Chief Executive Officer, stated: "Our Q2 financial results show our continued investment in research and development programs, mainly our Gaucher and Progranulin programs. We spent
In connection with the OTC Listing, the Company has applied for eligibility with The Depository Trust Company ("DTC"). Once approved, Sharp's common shares will be eligible to be electronically cleared and settled through DTC and will be considered "DTC eligible." This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors and brokers. It reduces transactional costs for participating brokerage firms, enabling the stock to be traded over a much wider selection of brokerage firms by coming into compliance with their requirements. DTC provides depository and book entry services, along with a settlement system for securities in the United States and across the globe. The organization is a member of the U.S. Federal Reserve System and a registered clearing agency with the U.S. Securities and Exchange Commission.
About Sharp Therapeutics Corp.
First-Choice Therapies for Genetic Diseases
Sharp Therapeutics is a pre-clinical stage company developing first-choice small-molecule therapeutics for genetic diseases. The Company's discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines.
For additional information on Sharp, please visit: .
Sharp Therapeutics Corp.
Scott Sneddon, PhD, JD
CEO/CSO
Email: [email protected]
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Sharp's current views and intentions with respect to future events, and current information available to Sharp, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Sharp in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Sharp does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Sharp undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit
FAQ
What is Sharp Therapeutics' (SHRXF) main business focus?
When will Sharp Therapeutics (SHRXF) begin Phase I clinical trials?
How much did Sharp Therapeutics increase their R&D spending in Q2 2025?
What is the significance of Sharp Therapeutics' OTCQB listing?
What technology does Sharp Therapeutics use for drug development?
